Table 2.
Comparison of values at baseline (BL) and after 6 months (M6) in patients with psoriatic arthritis (PsA) and controls
| Analytes | PsA (BL), n = 41 | PsA (M6), n = 41 | p-value PsA, BL vs M6 | Controls (BL), n = 39 | Controls (M6), n = 39 | p-value controls, BL vs M6 |
|---|---|---|---|---|---|---|
| TNF-α, pg/mL | 12.92 (9.99–17.20) | 12.49 (9.13–17.09) | 0.234 | 11.66 (8.49–13.54) | 9.60 (7.84–13.01) | 0.003 |
| IL-1β, pg/mLa | 12.86 (6.73–19.69) | 10.53 (5.02–19.69) | 0.231 | 12.13 (5.30–14.81) | 8.61 (5.30–14.28) | 0.048 |
| IL-6, pg/mLb | 8.72 (6.23–11.18) | 7.53 (5.34–10.03) | 0.444 | 7.23 (5.54–9.47) | 6.90 (4.92–8.33) | 0.005 |
| IL-8, pg/mLc | 18.69 (13.55–23.21) | 17.68 (13.53–21.65) | 0.781 | 19.28 (13.86–27.32) | 16.64 (11.85–19.41) | 0.077 |
| IL-12/IL-23 p40d, pg/mL | 602.65 (384.93–900.21) | 666.57 (333.38–974.17) | 0.978 | 544.11 (333.38–835.83) | 466.00 (209.26–729.91) | 0.032 |
| IL-13, pg/mLe | 906.55 (679.96–1131.63) | 885.07 (561.48–1171.12) | 0.377 | 885.07 (650.51–1103.93) | 777.97 (551.40–1023.60) | 0.053 |
| IL-17, pg/mLf | 2.63 (1.58–4.65) | 2.43 (0.41–4.48) | 0.074 | 0.86 (0.41–3.35) | 0.41 (0.41–2.63) | 0.465 |
| IL-23, ng/mLg | 0.40 (0.17–0.54) | 0.18 (0.10–0.30) | < 0.001 | 0.54 (0.33–0.71) | 0.23 (0.12–0.34) | < 0.001 |
| IFN-γ, pg/mL | 61.98 (43.73–76.34) | 52.09 (40.50–76.34) | 0.134 | 54.73 (43.83–69.95) | 48.80 (40.50–61.98) | 0.006 |
| Resistin, ng/mL | 12.83 (10.58–15.77) | 11.81 (10.05–14.91) | 0.341 | 11.82 (9.22–16.42) | 12.45 (9.19–15.04) | 0.315 |
| Leptin, ng/mLh | 26.28 (14.35–48.73) | 9.25 (4.40–16.24) | < 0.001 | 38.80 (20.47–59.87) | 14.04 (10.07–26.92) | < 0.001 |
| HMW adiponectin, µg/mL | 3.39 (2.13–5.12) | 5.95 (3.78–8.45) | < 0.001 | 4.26 (2.07–6.45) | 5.78 (4.50–7.93) | < 0.001 |
| Tot-adiponectin, µg/mL | 4.03 (3.18–6.06) | 5.90 (4.04–7.93) | < 0.001 | 4.16 (3.27–5.11) | 5.67 (4.27–6.70) | < 0.001 |
| VAS patients´ global disease activity, mm | 34 (19–61) | 12 (5–51) | 0.001 | |||
| VAS pain, mm | 30 (19–63) | 20 (5–52) | 0.004 | |||
| VAS fatigue, mm | 56 (22–67) | 25 (8–44) | 0.001 | |||
| HAQ, score | 0.63 (0.13–1.00) | 0.25 (0.00–0.69) | < 0.001 | |||
| DAS28CRP, score | 2.9 (2.1–3.7) | 2.5 (1.7–3.0) | < 0.001 | |||
| DAPSA, score | 15.3 (6.6–29.1) | 8.2 (2.8–17.7) | < 0.001 | |||
| BMI, kg/m2 | 35.2 (34.1–38.1) | 29.8 (26.6–31.5) | < 0.001 | 37.7 (36.7–41.5) | 30.4 (27.9–33.2) | < 0.001 |
| CRP, mg/L | 4.0 (2.0–8.5) | 2.0 (1.0–6.5) | 0.041 | 4.0 (2.0–6.0) | 2.0 (1.0–4.0) | < 0.001 |
Values are median (interquartile range) or n (%)
p-value for comparison between BL and M6 are based on cytokine levels above detection level, present in:
a31 patients with PsA and 28 controls, b41 patients with PsA and 38 controls, c41 patients with PsA and 38 controls, d35 patients with PsA and 29 controls, e40 patients with PsA and 37 controls, f20 patients with PsA and 19 controls, g35 patients with PsA and 38 controls, h40 patients with PsA and 38 controls
BL baseline, BMI body mass index, CRP c-reactive protein, DAPSA disease activity in psoriatic arthritis, DAS28CRP disease activity score, HAQ health assessment questionnaire, HMW high molecular weight, IFN interferon, IL interleukin, M6 month 6 after baseline, TNF tumor necrosis factor, Tot total, VAS visual analogue scale